Clinical Trial

A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-15; most recent amendment 2026-03-06.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-02
Trial Details
NCT Number NCT07293065
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions Herpes Zoster
Enrollment 12,000 participants
Start Date 2025-12-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10